OPK
OPKO HEALTH, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.61
+5.23%Year over year
Reported trailing growth
- Revenue
- -11.5%
- EBITDA
- -16.2%
- EBIT
- -2.6%
- EPS
- +59.3%
- Free cash flow
- +48.3%
- Operating cash flow
- +48.5%
Forward estimates
Based on analyst estimates
- Revenue
- -9.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -15.5%
- EBITDA
- —
- EBIT
- -44.0%
- Net income
- —
- EPS
- —
- Free cash flow
- +8.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026